Immune System Kills Potential Lymphomas 'Daily,' Say Researchers

New research indicates that potential lymphoma may be developing in the human body with alarming frequency but that the immune system plays an active role in eliminating this threat.

A team from Australia’s Walter and Eliza Hall Institute of Medical Research report in the journal Nature Medicine that spontaneous, cancerous immune B cells develop in the human body every day, but that the immune system wipes them out before they can become lymphoma.

The researchers regard the development of these spontaneous mutations as part of the normal function of the human body. They determined that when these develop, it is the immune system's T cells that are capable of detecting and killing the mutated cells. This was proven in an indirect way when researchers "turned off" the T cell response in an animal model and found that lymphoma developed at a rapid rate.

These findings are in line with the existing body of knowledge that shows how people with compromised immune systems are at a greater risk of developing lymphomas than people whose immune systems are not compromised.

The next step, according to Associate Professor David Tarlinton, would be a method of spotting pre-cancerous cells in the initial stages of their development, enabling early intervention for patients at risk of developing B-cell lymphoma:

In the majority of patients, the first sign that something is wrong is finding an established tumour, which in many cases is difficult to treat. Now that we know B-cell lymphoma is suppressed by the immune system, we could use this information to develop a diagnostic test that identifies people in early stages of this disease, before tumours develop and they progress to cancer. There are already therapies that could remove these ‘aberrant’ B cells in at-risk patients, so once a test is developed it can be rapidly moved towards clinical use.

Source: WEHI

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap